Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy

2017 ◽  
Vol 32 (8) ◽  
pp. 1512-1519 ◽  
Author(s):  
Yao-Chun Hsu ◽  
Lein-Ray Mo ◽  
Chi-Yang Chang ◽  
Ming-Shiang Wu ◽  
Tzeng-Huey Yang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Serum Viral Load ◽  
Virological Relapse

Detection of Hepatitis B Genotypes in HBsAg & HBeAg Carriers

2018 ◽  
Vol 7 (5) ◽  
Author(s):  
Salman Khan ◽  
Molly Madan
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Central Research ◽  
Elisa Kit ◽  
B Virus ◽  
Negative Chronic Hepatitis ◽  
Genotype A

Objective:- Hepatitis B is noteworthy medical issues that may include the late continuation of liver cirrhosis and hepatocellular carcinoma. The present study aimed for the detection and diffrentiation of Hepatitis B virus HBsAg inactive non-replicative carriers, HBeAg-positive inactive replicative carriers, active carriers & HBeAg-negative chronic hepatitis B by Real Time PCR and their genotyping Methods: This research conducted on 245 positive for HBsAg, 118 (48.16 %) were male and 127 (51.84%) were female patients, which was performed in central research station labortory of Microbiology at netaji subhash Chandra Bose subharti Medical College and Hospital, Meerut Between march 2016 to November 2017 The sera were separated and screened for HBsAg by ELISA kit. Positive samples for HBsAg were tested for HBeAg ELISA kit and DNA Viral load then sequenced for genotying Results:. Of the 245 HBsAg Positive case 55 (1.12%) were HBeAg positive. In 16 PCR positive and HBV genotyping, In HBsAg inactive Non-Replicative 37.5% (n=6) genotype-B and 6.25% (n=1) genotype-A, In HBeAg inactive Replicative 12.5% (n=2) genotype-B and 12.5% (n=2) genotype-A and In HBeAg Active Chronic Hepatitis B 18.75% (n=3) genotype-B and 12.5% (n=2) genotype-A were detected Conclusions: Management strategy, using HBsAg, HBeAg and HBV DNA viral load, seems adequate for the confirmation and diffrentiation of Hepatitis B virus inactive, active carriers & HBeAg-negative chronic hepatitis B patients and genotype B was more prevalent in comparission to genotype A. Distribution of carriers & genotypes, help physicians to prescribe proper antiviral/interferon therapy according to current genotyping pattern in this region Keywords: Hepatitis B virus, Carrier State, HBsAg, HBeAg, RT-PCR

Update in management of hepatitis B in pregnancy and prevention of mother to child hepatitis B transmission

2018 ◽  
Vol 1 (3) ◽  
pp. 1-8
Author(s):  
Naichaya Chamroonkul
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
High Viral Load ◽  
World Population ◽  
Hepatitis B Infection ◽  
Mother To Child Transmission ◽  
Child Transmission ◽  
Mother To Child

Even with two decades of widespread using hepatitis B vaccination, chronic hepatitis B remains a major global health problem. In Thailand, the prevalence of chronic hepatitis B infection was down from 8 - 10% in last decade to 5% recently. Failure to control mother to child transmission is one of the important barriers to the total elimination of hepatitis B infection from world population. In the majority, vertical transmission can be prevented with a universal screening program, immunoprophylaxis by administration of hepatitis B vaccine and hepatitis B immunoglobulin (HBIg) for babies born to mothers with HBV. However, in mothers with a high viral load, the chance of immunoprophylaxis failure remains high. To date, there are standard recommendations by all international liver societies including AASLD, EASL and APASL suggest introducing an antiviral agent during the third trimester to CHB pregnant women with a high viral load. Previous US FDA pregnancy category B agents such as Tenofovir and Telbivudine are allowed through all trimesters of pregnancy and are effective for prevention of mother to child transmission. Breastfeeding for patients who receive antiviral agents can be allowed after a risk-benefit discussion with the patient and family.

Comparison of the Efficacy of Entecavir and Tenofovir in Chronic Hepatitis B Patients With High Viral Load and/or High Fibrosis Scores at Week 48 of Therapy

2011 ◽  
Vol 140 (5) ◽  
pp. S-930-S-931 ◽  
Author(s):  
Ayse O. Kurdas Ovunc ◽  
Fatih Guzelbulut ◽  
Ebubekir Senates ◽  
Yasemin Gökden ◽  
Ayca G. Degirmenci Salturk ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
High Viral Load

scholarly journals Patterns of viral load in chronic hepatitis B patients in Brazil and their association with ALT levels and HBeAg status

2009 ◽  
Vol 8 (4) ◽  
pp. 339-345 ◽  
Author(s):  
Marcelo Eidi Nita ◽  
Nelson Gaburo ◽  
Hugo Cheinquer ◽  
Gilbert L’ltalien ◽  
Evaldo Stanislau Affonso de Araujo ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Hbeag Status

Five-Year Outcome of Telbivudine versus Entecavir in Treating High Viral Load Chronic Hepatitis B Patients

2016 ◽  
Vol 64 (2) ◽  
pp. S590-S591
Author(s):  
H.-Y. Pan ◽  
Z.-Z. Ren ◽  
H.-J. Huang ◽  
H. Zou ◽  
Y.-X. Tong ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
High Viral Load

ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B

2008 ◽  
Vol 42 (2) ◽  
pp. 160-164 ◽  
Author(s):  
M.J. ter Borg ◽  
B.E. Hansen ◽  
G. Bigot ◽  
B.L. Haagmans ◽  
H.L.A. Janssen
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Ifn Alpha ◽  
Positive Chronic Hepatitis
Sign in / Sign up

Export Citation Format

Share Document